SCHEMBL3077973

SCHEMBL3077973

O=C(Cc1coc(-c2ccc(OCCCN3CCCCC3)cc2)n1)N1CCCCC1

nearest known ligand 0.72

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 16/20 0.72
KCNH2 Q12809 7/20 0.51
TLR9 Q9NR96 3/20 0.51
TLR7 Q9NYK1 2/20 0.51
HRH1 P35367 1/20 0.48
HRH4 Q9H3N8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3080685 0.90 HRH3 (0.56) HRH3
SCHEMBL3078871 0.90 HRH3 (0.56) HRH3
SCHEMBL3081848 0.89 HRH3 (0.54) HRH3
SCHEMBL3080577 0.86 HRH3 (0.53) HRH3KCNH2HRH1
SCHEMBL3086217 0.86 HRH3 (0.53) HRH3KCNH2HRH1
SCHEMBL3078416 0.85 HRH3 (0.52) HRH3KCNH2HRH1
SCHEMBL3082345 0.84 HRH3 (1.00) HRH3KCNH2TLR9TLR7HRH1
SCHEMBL3081656 0.84 HRH3 (1.00) HRH3KCNH2TLR9TLR7HRH1
SCHEMBL3070984 0.84 HRH3 (1.00) HRH3KCNH2TLR9TLR7HRH1
SCHEMBL3073699 0.83 HRH3 (0.49) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US claimed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR HRH3 4/4885KCNH2 1005/4885TLR9 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.